Neuromeka Announces 126.58B KRW Rights Offering and 50% Stock Dividend - Discounted Issue Price of 39,600 KRW, Risks of Dilution and Price Decline
Rights offering: 3,196,465 new common shares (25.76% dilution), estimated issue price 39,600 KRW (20% discount), total proceeds ~126.58B KRW (facilities 80B, operations 36.58B, debt repayment 10B)
Stock dividend: 0.5 shares per existing share after the rights offering (7,802,808 shares), record date August 6, 2026, listing August 28, 2026
Existing shareholders receive transferable subscription rights (listed), followed by a public offering; final issue price determined as the lower of two calculated prices with a 60% floor
Estimated issue price of 39,600 KRW is approximately 23.8% below the current price of 52,000 KRW, raising concerns about value dilution and downward price pressure
[AI Summary]The combined rights offering and stock dividend will approximately double the number of shares outstanding, inevitably diluting existing shareholders, and the discounted issue price poses downside risk. However, the funds raised for facility investment and working capital support long-term growth, warranting a neutral rather than purely negative assessment.
KOSDAQ Filing Information
Filing: [Correction of Description] Report On Major Events (Decision On Paid-In And Free Capital Increase)